Administration advice :
-Extended/controlled/prolonged/sustained release tablet formulations should not be crushed or chewed.
-Take with food to decrease gastrointestinal side effects.
-This drug should be taken as the same time(s) each day.
Storage requirements :
-The manufacturer product information should be consulted.
-Lithium toxicity is related to serum lithium levels, and may occur at doses close to therapeutic levels.
-Patients in the manic phase are better able to tolerate lithium; tolerance to lithium decreases when manic symptoms subside.
-Mania is characterized by pressure of speech, motor hyperactivity, reduced sleep requirements, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and/or hostility. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of the episodes.
-ECG, especially in patients at risk of unmasking Brugada syndrome
-Thyroid function, especially in patients with thyroid disorders
-Renal function tests (., urinalysis, urine specific gravity, serum creatinine, creatinine clearance), especially in patients who develop polyuria and/or polydipsia
Patient advice :
-Patients should be told to seek immediate medical attention if signs/symptoms of Brugada syndrome, encephalopathic syndrome, or diabetes insipidus occur.
-Patients, family members, and/or caregivers should be instructed to discontinue therapy and immediately report any signs/symptoms of lithium toxicity, change in behavior, or suicidality.
-Inform patients that this drug may cause drowsiness, and they should avoid driving or operating machinery until the full effects of the drug are seen.
-Patients should be counseled on the importance of maintaining adequate salt and water intake.
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.